8-K: Stoke Therapeutics Announces Q3 2024 Financial Results and Provides Zorevunersen Development Update

Stoke Therapeutics reported its third quarter 2024 financial results, provided updates on its zorevunersen program, and announced plans to share new data by year-end.

Summary

• Stoke Therapeutics announced its financial results for the third quarter of 2024, with a net loss of $26.4 million, or $0.47 per share, compared to a net loss of $24.5 million, or $0.55 per share, for the same period in 2023.
• The company's revenue for the quarter was $4.9 million, up from $3.3 million in the same period last year, primarily from a collaboration agreement with Acadia Pharmaceuticals.
• Research and development expenses increased to $22.2 million for the quarter, compared to $20.3 million in the prior year, while general and administrative expenses rose to $12.7 million from $10.3 million.
• As of September 30, 2024, Stoke had $269.2 million in cash, cash equivalents, and marketable securities.
• The company is progressing discussions with regulatory agencies regarding a single global Phase 3 study for zorevunersen and plans to provide an update by year-end.
• Stoke also plans to present new data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in zorevunersen studies at the American Epilepsy Society meeting in December.
• The start of the Phase 1 study for STK-002, a treatment for autosomal dominant optic atrophy (ADOA), will be delayed as the company focuses on zorevunersen.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has made progress with its lead program and has a strong cash position, the increased net loss and delay in the STK-002 program are concerning. The focus on zorevunersen is positive, but the financial results and delay temper the overall outlook.

Positives

• Revenue increased to $4.9 million in Q3 2024 from $3.3 million in Q3 2023.
• The company has a strong cash position of $269.2 million as of September 30, 2024.
• Discussions with regulatory agencies regarding the Phase 3 study of zorevunersen are progressing.
• The FDA has removed the Partial Clinical Hold on zorevunersen.
• The company is planning to present new data on zorevunersen at the American Epilepsy Society meeting.

Negatives

• The company reported a net loss of $26.4 million for Q3 2024, compared to a net loss of $24.5 million for the same period in 2023.
• Research and development expenses increased to $22.2 million for the quarter, up from $20.3 million in the prior year.
• General and administrative expenses also increased to $12.7 million from $10.3 million in the same period last year.
• The start of the Phase 1 study for STK-002 has been delayed.

Risks

• The company's ability to obtain regulatory approval for zorevunersen is not guaranteed.
• Clinical trial results may not be replicated in subsequent trials.
• The company's ability to fund development activities is subject to market conditions and other factors.
• Global business, political, and macroeconomic conditions could impact the company's performance.
• The company faces risks related to intellectual property protection.

Future Outlook

The company plans to provide an update on Phase 3 registrational plans for zorevunersen by year-end and share new data from all patients treated with the proposed Phase 3 dosing regimen. They also plan to continue discussions with regulatory agencies regarding the Phase 3 study design.

Management Comments

• Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics, stated that they are headed into a busy year-end as they prepare to share new data and complete regulatory discussions.
• He also mentioned that the company has demonstrated substantial and sustained effects across multiple measures of disease in their studies of zorevunersen, giving them confidence in their Phase 3 planning.

Industry Context

This announcement is relevant to the biotechnology industry, particularly companies focused on developing treatments for rare genetic diseases. The focus on RNA medicine and antisense oligonucleotides is a growing trend in the industry. The company's progress with zorevunersen for Dravet syndrome is being closely watched by investors and the medical community.

Comparison to Industry Standards

• Stoke's Q3 2024 net loss of $26.4 million is within the range of other clinical-stage biotech companies, but the increase in operating expenses is a point of concern.
• The company's cash position of $269.2 million is relatively strong compared to other companies of similar size, providing a runway for continued development.
• The progress of zorevunersen is comparable to other companies developing treatments for rare genetic diseases, such as BioMarin Pharmaceutical and Sarepta Therapeutics, which have also faced regulatory hurdles and clinical trial challenges.
• The delay in the STK-002 program is not uncommon in the biotech industry, where companies often prioritize their lead programs.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the delay in the STK-002 program.
• Patients with Dravet syndrome and their families may be encouraged by the progress of zorevunersen.
• Employees may be affected by the shift in focus towards zorevunersen and the delay in the STK-002 program.
• The company's collaboration with Acadia Pharmaceuticals is a positive sign for future revenue.

Next Steps

• The company plans to provide an update on Phase 3 registrational plans for zorevunersen by year-end.
• Stoke will present new data on zorevunersen at the American Epilepsy Society meeting in December.
• The company will continue discussions with regulatory agencies regarding the Phase 3 study design for zorevunersen.

Key Dates

Keywords

zorevunersen, Dravet syndrome, RNA medicine, antisense oligonucleotide, clinical trials, Phase 3 study, STK-002, financial results, biotechnology, epilepsy